Frontlight ResearchEarly access
CompletedPhase 1/2
RGX-121 Gene Therapy in Children 5 Years of Age and Over With MPS II (Hunter Syndrome)
Key facts
- Who runs it
- REGENXBIO Inc.
- Where
- Oakland, United StatesSee the siteAlso in 1 other country, 1 site
- Trial code
- Status
- Completed
- Phase
- Phase 1/2
- People taking part
- 6 people enrolled
- Started
- 11 Mar 2021
- Ended
- 23 May 2024
- Type of study
- Interventional
- Treatments tested
- RGX-121
- Record updated
- 28 January 2025
Who can take part
- Age
- 5 years to 17 years
- Sex
- Men only
- Healthy volunteers
- Cannot take part
Show the full registry criteria (14)Hide the full registry criteria
Who can take part
- Meets any of the following criteria:
- Has a documented diagnosis of MPS II AND a neurocognitive testing score ≤ 1 ½ standard deviation (SD) from the test normative mean (BSID-III: 77 and MSEL Visual Reception: 35), OR
- Has a documented diagnosis of MPS II AND has a decline of ≥ 1 standard deviation on serial neurocognitive testing administered between 3 to 36 months apart (BSID-III Cognitive or MSEL Visual Reception), OR
- Has a relative clinically diagnosed with neuronopathic MPS II who has the same IDS mutation as the participant AND the participant in the opinion of a geneticist has inherited a neuronopathic form of MPS II, OR
- Has documented mutation(s) in IDS that in the opinion of a geneticist is known to result in a neuronopathic phenotype AND in the opinion of a clinician has a neuronopathic form of MPS II
Who cannot take part
- Has contraindications for immunosuppressive therapy
- Has had prior treatment with an AAV-based gene therapy product
- If receiving ELAPRASE® via intrathecal (IT) administration, must agree to discontinue IT idursulfase for the duration of the study
- Is currently failing to respond to idursulfase (ELAPRASE®) IV due to neutralizing anti-idursulfase antibodies
- Has received any investigational product within 30 days of Day 1 or 5 half-lives before signing of the ICF, whichever is longer
- Has any neurocognitive deficit not attributable to MPS II or diagnosis of a neuropsychiatric condition
- Has experienced a serious hypersensitivity reaction to intravenous (IV) ELAPRASE®
- Has a platelet count <100,000 per microliter (µL), absolute neutrophil count <1.0 × 103/µL, or aminotransferase (ALT) or aspartate aminotransferase (AST) >3 × upper limit of normal (ULN) or total bilirubin >1.5 × ULN at screening unless the participant has a previously known history of Gilbert's syndrome
- Has contraindications for intracisternal injection, intracerebroventricular injection, or lumbar puncture
Where in United States
Also in 1 other country, 1 site
- University of California San Francisco, Benioff Children's HospitalOakland, United States
About the trial
What the trial wants to find out
RGX-121 is a gene therapy which is designed to deliver a functional copy of the iduronate-2-sulfatase (IDS) gene to the central nervous system. This study is a phase I/II study to determine whether RGX-121 is safe, well tolerated, and potentially effective in children five years of age and over who have severe MPS II.
The group in the trial
- Single ArmTreatment being tested
6.5 × 10\^10 GC/g brain mass of RGX-121
Treatment: RGX-121
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase I/II Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of RGX-121 in Children 5 Years of Age and Older With MPS II (Hunter Syndrome)
- Record updated
- 28 January 2025